SCHEMBL2211570

SCHEMBL2211570

O=C(O)Cc1n[nH]c(S)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.31
CSNK2A2 P19784 1/20 0.31
CSNK2B P67870 1/20 0.31
CSNK2A1 P68400 1/20 0.31
CSNK2A3 Q8NEV1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
GABRA1 P14867 1/20 0.31
TSHR P16473 1/20 0.31
NFKB1 P19838 1/20 0.31
GABRR1 P24046 1/20 0.31
GABRR2 P28476 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRB2 P47870 1/20 0.31
GABRA4 P48169 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11528858 0.98 CYP1A2 (0.41) CYP1A2LMNAPOLBCSNK2A2CSNK2B
SCHEMBL873583 0.75 POLB (0.50) CYP1A2LMNAPOLBALDH1A1CYP3A4
SCHEMBL1686950 0.75 CYP1A2 (0.52) CYP1A2LMNAPOLBALDH1A1GABRA5
SCHEMBL28670137 0.73
SCHEMBL3302769 0.73
SCHEMBL12472912 0.72 CYP1A2 (0.39) CYP1A2LMNAALDH1A1TSHR
SCHEMBL874320 0.71 CYP1A2 (0.38) CYP1A2LMNAPOLBALDH1A1
SCHEMBL12473222 0.71 LMNA (0.41) CYP1A2LMNAPOLB
SCHEMBL878583 0.71 ADORA2A (0.40) CYP1A2LMNAPOLB
SCHEMBL11603299 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114436979-A Method for synthesizing 1,2, 4-triazole-3-methyl carboxylate 成都化润药业有限公司 2022-05-06 CN disclosed
CN-111471027-B Synthesis process of ribavirin intermediate and intermediate 广安润康药业有限公司 2021-09-28 CN disclosed
CN-111471027-A Synthesis process of ribavirin intermediate and intermediate 广安润康药业有限公司 2020-07-31 CN disclosed
EP-2906640-B1 COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, METHODS FOR MAKING AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING PRC DESOTO INT INC (US) 2017-11-15 EP disclosed
EP-2756043-B1 COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING PRC DESOTO INT INC (US) 2017-04-12 EP disclosed
US-9181628-B2 Coating/sealant systems, aqueous resinous dispersions, and methods of electrocoating PRC-DESOTO INTERNATIONAL, INC. (US) 2015-11-10 US disclosed
EP-2906640-A1 COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, METHODS FOR MAKING AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING PRC-Desoto International, Inc. (US) 2015-08-19 EP disclosed
US-9029437-B2 Coating/sealant systems, aqueous resinous dispersions, methods for making aqueous resinous dispersions, and methods of electrocoating PRC-DESOTO INTERNATIONAL, INC. (US) 2015-05-12 US disclosed
EP-2756043-A2 COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING PRC-Desoto International, Inc. (US) 2014-07-23 EP disclosed
EP-1952918-B1 METHOD FOR PRODUCING METAL PARTICLE DISPERSION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM TOYO INK MFG CO (JP) 2013-05-22 EP disclosed
US-20110175040-A1 METHOD FOR PRODUCING METAL PARTICLE DISPRESION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM TOYO INK MFG CO., LTD. (JP) 2011-07-21 US disclosed
US-7981327-B2 Method for producing metal particle dispersion, conductive ink using metal particle dispersion produced by such method, and conductive coating film TOYO INK MFG. CO. LTD. (JP) 2011-07-19 US disclosed
US-20090258202-A1 Method for Producing Metal Particle Dispersion, Conductive Ink Using Metal Particle Dispersion Produced by Such Method, and Conductive Coating Film GVP GESELLSCHAFT ZUR VERMARKTUNG DER PORENBRENNERTECHNIK MBH (DE) 2009-10-15 US disclosed
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed
EP-1953148-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-08-06 EP disclosed
EP-1952918-A1 METHOD FOR PRODUCING METAL PARTICLE DISPERSION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM Toyo Ink Mfg. Co., Ltd (JP) 2008-08-06 EP disclosed
US-4183925-A 7-Aminophenylacetamido-Δ3 -cephem antibacterial agents and method of use PFIZER INC. (US) 1980-01-15 US disclosed
US-4142046-A BACTERICIDES, 7-AMINO-CEPHALOSPORINS SMITHKLINE CORPORATION (US) 1979-02-27 US disclosed
US-4060610-A Pharmaceutical compositions comprising 7-acyl-3-(substituted triazolyl thiomethyl)-cephalosporins and methods of treating bacterial infections SMITHKLINE CORPORATION (US) 1977-11-29 US disclosed
US-3989694-A ANTIBACTERIAL SMITHKLINE CORPORATION (US) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF MMP2, MMP9, MMP1 CYP1A2 471/4885LMNA 3074/4885POLB 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.